IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, November 2026
Impact Factor: 8.2

Lipid Nanoparticles in Drug and Gene Delivery: Current Advances and Future Perspectives

Roshan Akotkar[1] , Dr. Vidhya Thorat[2*], Dr. Pravin Sable[3], Joel Chakranarayan[4], Dhanshree Badadhe[5]
[1,2,3,4,5]SSP Shikshan Sanstha's Siddhi College of Pharmacy, Navlevasti, Chikhali, PCMC Pune

Abstract: *As a cutting-edge non-viral delivery system, lipid nanoparticles (LNPs) are revolutionizing the treatment of drugs and nucleic acids. LNPs are now recognized as adaptable, clinically validated nanocarriers due to their clinical success, as evidenced by approved siRNA therapies and extensively used mRNA vaccines. In order to facilitate effective intracellular cargo release, modern LNPs employ ionizable lipids, which are neutral under physiological conditions but become positively charged in acidic endosomes. Stability, encapsulation efficiency, biodistribution, and therapeutic efficacy have all been enhanced by developments in lipid chemistry, microfluidic manufacturing, surface engineering, and artificial intelligence-assisted formulation. However, obstacles to wider use still include low tissue specificity, ineffective endosomal escape, immunogenicity, production difficulties, and long-term safety. The evolution, composition, formulation, delivery methods, therapeutic uses, clinical translation, regulatory issues, and upcoming tactics like organ-selective targeting and CRISPR-Cas gene editing are all covered in this review.*

Keywords: Lipid nanoparticles; Drug delivery; Gene delivery; mRNA therapeutics; Ionizable lipids; Nanomedicine

I. INTRODUCTION

The ability to deliver therapeutic molecules safely and efficiently to their intended biological target remains one of the most important challenges in pharmaceutical sciences. Although remarkable progress has been achieved in drug discovery during the past few decades, the successful translation of many promising therapeutic agents into clinical practice continues to be limited by poor aqueous solubility, inadequate bioavailability, rapid enzymatic degradation, systemic toxicity, unfavorable pharmacokinetic profiles, and the inability to cross complex biological barriers. These limitations are particularly pronounced for nucleic acid therapeutics, including messenger RNA (mRNA), small interfering RNA (siRNA), microRNA (miRNA), plasmid DNA, and CRISPR-Cas gene-editing systems, all of which are highly susceptible to degradation by extracellular nucleases and exhibit poor cellular uptake because of their large molecular size and negative surface charge. [1]

Nanotechnology has emerged as an effective strategy to address these limitations by providing carrier systems capable of protecting therapeutic molecules while improving their pharmacokinetic and pharmacodynamic characteristics. Among the various nanocarriers investigated—including polymeric nanoparticles, dendrimers, inorganic nanoparticles, liposomes, and viral vectors—lipid nanoparticles have gained exceptional attention because they combine the advantages of high biocompatibility, biodegradability, efficient drug encapsulation, and scalable manufacturing. Their ability to deliver both conventional drugs and genetic materials has established LNPs as one of the most promising delivery platforms in modern pharmaceutics.[2]

The rapid clinical translation of lipid nanoparticles represents one of the most significant achievements in pharmaceutical nanotechnology[3]. Their therapeutic potential was first validated by the approval of patisiran, the first FDA-approved siRNA therapeutic formulated using lipid nanoparticles. Shortly thereafter, the unprecedented global success of mRNA-based COVID-19 vaccines further demonstrated that LNP technology could safely and effectively deliver fragile nucleic acids on a large commercial scale. These milestones transformed lipid nanoparticles from an

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, November 2026
Impact Factor: 8.2

experimental research platform into a clinically established technology and accelerated worldwide investment in RNA therapeutics, personalized medicine, cancer immunotherapy, and gene editing.[4]

Modern lipid nanoparticles differ substantially from conventional liposomes in both composition and mechanism of action. Rather than acting merely as passive vesicular carriers, LNPs are highly engineered nanosystems designed to overcome multiple biological barriers encountered during systemic delivery. A typical formulation consists of four principal components: ionizable lipids, phospholipids, cholesterol, and polyethylene glycol (PEG)-lipids. Each component contributes distinct physicochemical and biological functions that collectively determine nanoparticle stability, circulation time, biodistribution, cellular uptake, endosomal escape, and intracellular release of therapeutic cargo. Among these components, ionizable lipids are regarded as the cornerstone of contemporary LNP technology because they enable efficient nucleic acid encapsulation while minimizing systemic toxicity through their pH-responsive behavior.[5]

Despite these remarkable advances, several important scientific challenges remain unresolved. One of the most significant obstacles is inefficient endosomal escape, as only a small proportion of internalized nanoparticles successfully release their cargo into the cytoplasm before degradation within lysosomes. Furthermore, systemically administered LNPs predominantly accumulate in the liver because of interactions with circulating plasma proteins and hepatic clearance mechanisms, thereby limiting their effectiveness for diseases affecting other organs[6]. Additional concerns include immunogenicity associated with repeated administration, complement activation, formulation stability during long-term storage, manufacturing reproducibility, and regulatory considerations for emerging gene-editing therapies. These limitations continue to stimulate intensive research aimed at improving lipid chemistry, intracellular trafficking, tissue-specific targeting, and manufacturing technologies.[7]

II. EVOLUTION OF LIPID NANOPARTICLES

One of the most important developments in pharmaceutical nanotechnology is the creation of lipid nanoparticles (LNPs), which are the result of over 50 years of advancements in molecular medicine, formulation science, and lipid chemistry. The need to circumvent the biological constraints of traditional drug delivery methods while offering a secure and effective platform for the transportation of therapeutic molecules, especially nucleic acids, has propelled the development of LNPs.

The first description of phospholipid vesicles, later known as liposomes, by Bangham and colleagues in 1965 laid the groundwork for lipid-based medication delivery. These vesicular devices showed that phospholipids could self-assemble into bilayer structures that could trap lipophilic and hydrophilic medications.Poor physical stability, quick reticuloendothelial system clearance, low encapsulation efficiency for nucleic acids, and complicated manufacturing procedures all impeded the clinical translation of liposomes, despite their superior biocompatibility and decreased toxicity.

In the early 1990s, scientists developed solid lipid nanoparticles (SLNs) as a solution to these problems. In contrast to liposomes, SLNs have a solid lipid core that is maintained by surfactants, which enhances drug stability and permits regulated drug release. However, drug expulsion during storage was often induced by highly organized crystalline formations, which decreased loading capacity..[8]

Nanostructured lipid carriers (NLCs), which combine liquid and solid lipids to form imperfect crystalline matrices that may hold larger amounts of medicinal compounds, were the result of later innovation. Compared to SLNs, NLCs showed better encapsulation efficiency, increased physical stability, and more regulated drug release, making them appropriate for a wider range of pharmaceutical applications.

The development of ionizable lipid nanoparticles marked a significant turning point in the field of nucleic acid delivery. Because their persistent positive charge encouraged nonspecific interactions with plasma proteins and cellular membranes, earlier cationic lipid formulations shown significant toxicity despite efficiently condensing negatively charged nucleic acids. Ionizable lipids used pH-dependent behavior to get around this restriction..[9] They minimize systemic toxicity by remaining mostly neutral at physiological pH, but they become protonated in acidic endosomes,

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 3, November 2026 Impact Factor: 8.2

which facilitates membrane instability and the effective cytoplasmic release of therapeutic cargo. This breakthrough, which continues to be the hallmark of modern LNP technology, greatly increased both safety and transfection efficiency.

A number of significant clinical successes demonstrated the therapeutic potential of LNPs. The first siRNA treatment administered via LNP technology, patisiran, was approved in 2018, proving that non-viral lipid carriers may accomplish clinically significant gene silencing in humans. This achievement increased funding for RNA therapies and justified decades of study.. Shortly thereafter, the unprecedented success of mRNA-based COVID-19 vaccines further established LNPs as a clinically mature delivery platform capable of protecting fragile nucleic acids, supporting intracellular translation, and enabling rapid large-scale manufacturing. Shortly thereafter, the unprecedented success of mRNA-based COVID-19 vaccines further established LNPs as a clinically mature delivery platform capable of protecting fragile nucleic acids, supporting intracellular translation, and enabling rapid large-scale manufacturing.

The current generation of LNPs has evolved beyond passive carriers into highly engineered nanostructures. Contemporary research focuses on biodegradable ionizable lipids, selective organ-targeting (SORT) nanoparticles, biomimetic lipid systems, antibody-functionalized nanoparticles, and AI-assisted molecular design. Recent computational approaches now predict lipid pKa values, optimize molecular structures, and reduce experimental screening, marking a transition from empirical formulation development toward rational engineering.[10]

LNPs continue to evolve despite tremendous advancements. Even though intracellular transport has significantly improved with current formulations, significant obstacles such immunogenicity, ineffective endosomal escape, limited extrahepatic targeting, and large-scale manufacturing consistency continue to spur innovation. As a result, programmable lipid structures that can provide organ-specific distribution while maintaining acceptable safety profiles are becoming more and more the focus of current research.

Table 1. Historical evolution of lipid-based nanocarriers

Period	Major development	Key advantages	Major limitations
1965	Liposomes	Excellent biocompatibility	Poor stability, low nucleic acid delivery
Early 1990s	Solid Lipid Nanoparticles (SLNs)	Controlled drug release, improved stability	Drug expulsion due to lipid crystallization
Late 1990s	Nanostructured Lipid Carriers (NLCs)	Higher drug loading, improved stability	Formulation complexity
2000–2015	Ionizable Lipid Nanoparticles	High nucleic acid encapsulation, reduced toxicity	Predominant liver accumulation
2018–Present	Clinical LNP Platforms	FDA-approved siRNA therapy, mRNA vaccines	Tissue specificity and endosomal escape remain challenging

III. CLASSIFICATION OF LIPID-BASED NANOCARRIERS

The family of nanoscale delivery systems known as lipid-based nanocarriers is varied in terms of composition, internal architecture, preparation techniques, and therapeutic uses. Despite having similar lipid components, these systems' structural arrangement has a significant impact on intracellular transport, drug loading, release kinetics, stability, and biodistribution. Choosing the right carrier for a given pharmaceutical use requires an understanding of these differences.[2]

3.1 Liposomes

Liposomes are spherical vesicles with an aqueous core encircled by one or more phospholipid bilayers. Because of their superior biocompatibility and capacity to encapsulate both hydrophilic and lipophilic molecules, they continue to be among the most researched nanocarriers.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 3, November 2026 Impact Factor: 8.2

Numerous liposomal formulations have been used in therapeutic settings, especially in antifungal therapy and oncology. However, typical liposomes have a number of drawbacks, such as poor intracellular delivery, fast absorption by the mononuclear phagocyte system, instability during storage, and comparatively low encapsulation effectiveness for nucleic acids. As a result, while liposomes are still useful drug carriers, ionizable LNPs are typically more appropriate for modern gene delivery.[2]

3.2 Solid Lipid Nanoparticles

Physiologically appropriate solid lipids distributed in an aqueous surfactant solution make up solid lipid nanoparticles. Their solid matrix allows for continuous drug release while shielding encapsulated medications from chemical deterioration. SLNs show better biocompatibility and comparatively easy large-scale production as compared to polymeric nanoparticles.

Nevertheless, during storage, polymorphism changes may result in highly structured crystalline structures that drive out integrated medications, decreasing encapsulation effectiveness and jeopardizing long-term stability. These disadvantages prompted the creation of more sophisticated lipid carrier systems.[11]

3.3 Nanostructured Lipid Carriers

To overcome the drawbacks of SLNs, nanostructured lipid carriers were created. NLCs minimize medication loss during storage by combining solid and liquid lipids to form an imperfect internal matrix that can hold larger amounts of medicinal compounds.[12]

Because of their increased loading capacity, superior stability, and flexible release characteristics, NLCs have shown great promise for oral, topical, ophthalmic, pulmonary, and transdermal drug administration. However, compared to ionizable LNPs, their use in nucleic acid delivery is still somewhat restricted.[13]

3.4 Lipid Nanoparticles (LNPs)

The most sophisticated class of lipid-based delivery technologies currently in use is represented by contemporary lipid nanoparticles. LNPs have a highly ordered internal lipid matrix where ionizable lipids intimately link with nucleic acid cargo, in contrast to liposomes, which have continuous phospholipid bilayers encasing water compartments.

A typical LNP formulation contains four essential components:

Ionizable lipid

Helper phospholipid

Cholesterol

Polyethylene glycol (PEG)-lipid

Particle stability, encapsulation effectiveness, circulation time, biodistribution, and intracellular delivery are all determined by the combined physicochemical functions of each component. The significance of logical molecular design is further highlighted by recent research showing that minute structural changes of ionizable lipids can significantly change endosomal escape, organ tropism, and therapeutic efficacy.

3.5 Emerging Lipid-Based Nanocarriers

The rapid expansion of RNA therapeutics has stimulated the development of several next-generation lipid delivery systems, including:

Selective organ-targeting (SORT) nanoparticles

Biomimetic lipid nanoparticles

Antibody-functionalized LNPs

Stimuli-responsive lipid nanoparticles

Hybrid lipid–polymer nanoparticles

AI-designed ionizable lipid nanoparticles

Because small changes in lipid composition can reroute biodistribution from the liver to organs like the lung or spleen, SORT nanoparticles are among the most promising developments among them. This opens up new therapeutic options for conditions other than hepatic illnesses. Another game-changing strategy that makes it possible to predict the physicochemical characteristics of lipids and speeds up formulation optimization is AI-assisted lipid discovery.[14]

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, November 2026
Impact Factor: 8.2

Table 2. Classification of lipid-based nanocarriers

Nanocarrier	Structural characteristics	Advantages	Limitations	Major applications
Liposomes	Phospholipid bilayer vesicles	Excellent biocompatibility	Limited nucleic acid delivery	Drug delivery, oncology
Solid Lipid Nanoparticles	Solid lipid matrix	Controlled drug release	Drug expulsion during storage	Oral and topical delivery
Nanostructured Lipid Carriers	Mixed solid and liquid lipid matrix	Higher loading capacity	More complex formulation	Controlled drug delivery
Lipid Nanoparticles	Ionizable lipid matrix with helper lipids	Superior nucleic acid delivery, scalable manufacturing	Liver tropism, endosomal escape limitations	mRNA, siRNA, CRISPR, vaccines
SORT Nanoparticles	Modified LNPs with targeting lipids	Organ-selective delivery	Early stage of development	Precision medicine, gene therapy

IV. STRUCTURAL COMPONENTS AND DESIGN PRINCIPLES OF LIPID NANOPARTICLES

Instead of being straightforward lipid vesicles, modern lipid nanoparticles (LNPs) are complex nanoscale delivery systems. LNPs have a highly ordered internal architecture where ionizable lipids, helper lipids, cholesterol, polyethylene glycol (PEG)-lipids, and therapeutic nucleic acids interact to form stable nanostructures, in contrast to conventional liposomes, which are mainly composed of phospholipid bilayers encasing an aqueous compartment. Each component has a unique physicochemical function, and even little modifications to the lipid content can significantly affect the stability, biodistribution, intracellular trafficking, and therapeutic efficacy of nanoparticles. As a result, modern LNPs are designed using a logical structure-function approach, where each component is tuned to get past particular biological obstacles that arise during systemic drug administration.[1,5]

4.1 Ionizable lipids: the functional core of modern LNPs

Ionizable lipids are widely regarded as the most important component of LNP formulations because they determine nucleic acid encapsulation, intracellular delivery efficiency, and overall safety. Unlike permanently cationic lipids, ionizable lipids remain largely uncharged at physiological pH (≈7.4), thereby minimizing interactions with serum proteins and reducing systemic toxicity. Following cellular internalization, the acidic environment of the endosome protonates the ionizable amine groups, generating positively charged lipids that interact with negatively charged endosomal phospholipids. This interaction destabilizes the endosomal membrane and facilitates the release of therapeutic cargo into the cytoplasm.[5]

One of the biggest developments in nucleic acid delivery is the switch from permanently cationic lipids to ionizable lipids. Although early cationic methods showed effective nucleic acid condensation, they were linked to dose-limiting toxicity, hemolysis, complement activation, and inflammatory reactions. These problems were mostly resolved by ionizable lipids while retaining high transfection efficiency. It is currently acknowledged that their physicochemical characteristics, such as pKa, hydrophobic tail structure, linker chemistry, and biodegradability, are important factors in determining therapeutic efficacy.

The function of ionizable lipids has been further extended beyond endosomal escape by recent research. To increase biodegradation, decrease immunogenicity, and improve tissue selectivity, new lipid structures are being developed. Artificial intelligence and high-throughput screening are also speeding up the search for novel ionizable lipids by forecasting important factors like apparent pKa and delivery efficiency prior to experimental

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, November 2026
Impact Factor: 8.2

4.2 Helper phospholipids

During intracellular trafficking, helper phospholipids support membrane fusion and offer structural stability. DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine) and DOPE (dioleoylphosphatidylethanolamine) are the most often used phospholipids.

DSPC adds to the structural rigidity and long-term stability of LNP formulations and has a high phase transition temperature. On the other hand, DOPE's cone-shaped molecular structure encourages the creation of non-bilayer hexagonal phases, which improves endosomal escape and membrane fusion. The intended therapeutic use and the required balance between stability and intracellular delivery determine which of these phospholipids is best.[9]

4.3 Cholesterol

Because cholesterol improves membrane packing, mechanical stability, and nanoparticle integrity, it is included in nearly all clinically approved LNP formulations. In addition to its structural function, cholesterol affects the fluidity of membranes and promotes interactions with cellular membranes during absorption.[15]

According to recent studies, modified cholesterol analogues can dramatically change intracellular trafficking and increase the effectiveness of nucleic acid delivery. These results imply that cholesterol should be considered an active regulator of LNP activity rather than a passive structural element.[16]

4.4 PEG-lipids

By decreasing opsonization and phagocytic cell absorption, polyethylene glycol (PEG)-lipids create a hydrophilic corona around the surface of the nanoparticles, preventing aggregation during formulation and extending systemic circulation.

PEGylation offers a complicated trade-off in spite of these advantages. Excessive PEG density may decrease intracellular delivery and cellular absorption while lengthening circulation time. Furthermore, anti-PEG antibodies and faster blood clearance in certain people have been linked to repeated administration of PEG-containing formulations. The development of cleavable PEG-lipids and other stealth techniques that maintain extended circulation without sacrificing therapeutic efficacy is thus receiving a lot of attention.[17]

Table 3. Functional roles of major LNP components

Component	Primary function	Additional role	Representative examples
Ionizable lipid	Nucleic acid encapsulation	Endosomal escape, tissue targeting	DLin-MC3-DMA, SM-102, ALC-0315
Helper phospholipid	Structural stability	Membrane fusion	DSPC, DOPE
Cholesterol	Membrane stabilization	Intracellular trafficking	Cholesterol
PEG-lipid	Colloidal stability	Extended circulation	DMG-PEG2000

V. FORMULATION STRATEGIES AND MANUFACTURING TECHNOLOGIES

Lipid composition and reliable production techniques that can yield repeatable particles with regulated physicochemical properties are both necessary for the clinical application of lipid nanoparticles. Formulation approach has a significant impact on parameters like particle size, polydispersity index (PDI), encapsulation efficiency, and residual solvent concentration. As a result, continuous, highly regulated microfluidic processes that meet industrial quality standards have replaced traditional bulk mixing methods in manufacturing.[1,18]

5.1 Ethanol injection

One of the first methods for creating lipid nanoparticles was ethanol injection. Solvent exchange drives spontaneous self-assembly when lipids dissolved in ethanol are quickly combined with an aqueous phase that contains nucleic acids. Despite being straightforward and affordable, this technique frequently results in particles with wider size distributions and worse reproducibility, which makes it less appropriate for large-scale commercial manufacture.[19]

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, November 2026
Impact Factor: 8.2

5.2 Thin-film hydration

In thin-film hydration, lipids are dissolved in an organic solvent, the solvent is evaporated to create a thin lipid film, and the film is then hydrated with an aqueous solution that contains the medicinal payload. Although this method is popular for laboratory-scale preparation, it is less appealing for commercial LNP production since it necessitates further size-reduction procedures like sonication or extrusion.[19]

5.3 Microfluidic mixing

Because microfluidic mixing allows for the quick and highly repeatable creation of nanoparticles under regulated mixing conditions, it has emerged as the favored manufacturing process for contemporary LNPs. Lipid and aqueous streams collide in microchannels during this process, resulting in incredibly quick solvent exchange that encourages consistent self-assembly. Microfluidics provides better control over particle size, a narrow size distribution, high encapsulation efficiency, and scalability that complies with current Good Manufacturing Practice (cGMP) when compared to conventional approaches. Because of these benefits, microfluidics is now the most popular technology for producing mRNA-LNP medicines commercially[19].

5.4 Critical quality attributes

The therapeutic performance of LNPs is highly dependent on several critical quality attributes:

Particle size (typically 60–120 nm)

Polydispersity index (PDI < 0.2)

Encapsulation efficiency (>90% for many RNA formulations)

Surface charge (near-neutral zeta potential)

Sterility and endotoxin levels

Residual solvent content

Long-term physicochemical stability

Minor deviations in these parameters may substantially alter biodistribution, pharmacokinetics, and therapeutic efficacy. Consequently, rigorous quality control is essential during both development and large-scale manufacturing.[20]

Table 4. Comparison of major LNP manufacturing techniques

Technique	Advantages	Limitations	Industrial suitability
Ethanol injection	Simple, economical	Broad size distribution	Low
Thin-film hydration	Versatile	Labor-intensive, variable particle size	Moderate
High-pressure homogenization	Scalable	High energy consumption	High
Microfluidic mixing	Uniform particles, excellent reproducibility, high encapsulation efficiency	Higher equipment cost	Excellent

VI. PHYSICOCHEMICAL CHARACTERIZATION OF LIPID NANOPARTICLES

Because observable physicochemical parameters directly affect the biological performance of lipid nanoparticles (LNPs), physicochemical evaluation is an essential step in their development. Biodistribution, cellular uptake, intracellular trafficking, pharmacokinetics, and therapeutic efficacy are all influenced by factors such particle size, size distribution, surface charge, encapsulation efficiency, morphology, colloidal stability, and lipid composition. Comprehensive characterisation is crucial for both research and clinical translation since regulatory bodies view these factors as key quality attributes (CQAs).[18,20]

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 3, November 2026 Impact Factor: 8.2

6.1 Particle size

One of the most important factors influencing LNP performance is particle size. The sizes of the majority of therapeutically effective LNP formulations range from 60 to 120 nm. While avoiding quick renal clearance or substantial splenic filtration, nanoparticles in this range typically show extended circulation, effective tissue penetration, and positive cellular uptake. Phagocytic cells are more likely to identify particles larger than about 200 nm, while very small nanoparticles may show altered biodistribution and decreased encapsulation effectiveness. Recent research also shows that intracellular trafficking, organ tropism, and protein corona formation are all impacted by particle size. Thus, consistent therapeutic effectiveness depends on maintaining a limited particle-size distribution.[20]

Analytical techniques

Dynamic Light Scattering (DLS)

Nanoparticle Tracking Analysis (NTA)

Cryogenic Transmission Electron Microscopy (Cryo-TEM)

6.2 Polydispersity Index (PDI)

The PDI describes the uniformity of particle size within a formulation. A low PDI indicates homogeneous nanoparticles, whereas a high PDI reflects significant variability.

Generally accepted values are:

PDI	Interpretation
<0.20	Excellent uniformity
0.20–0.30	Acceptable
>0.30	Poor formulation quality

Low PDI values improve reproducibility, storage stability, and manufacturing consistency, all of which are particularly important for GMP production.

6.3 Zeta potential

Zeta potential reflects the electrical potential at the nanoparticle surface and provides important information regarding colloidal stability.

Unlike early cationic nanoparticles, modern LNPs exhibit nearly neutral surface charges under physiological conditions due to ionizable lipids.

Typical values:

−10 mV to +10 mV

This near-neutral surface minimizes nonspecific protein adsorption and systemic toxicity while maintaining sufficient stability.

During endosomal acidification, ionizable lipids become protonated, increasing positive charge locally and promoting membrane destabilization.[5,22]

6.4 Encapsulation efficiency

Encapsulation efficiency (EE%) represents the percentage of therapeutic molecules successfully incorporated within nanoparticles.

It is calculated as:

EE (%) = (Encapsulated drug / Total drug) × 100

Encapsulation efficiencies of over 90% are often attained by commercial RNA-LNP formulations, which enhances therapeutic potency and minimizes manufacturing waste. Buffer pH, lipid composition, flow-rate ratio during microfluidic mixing, and lipid-to-RNA ratio all have a significant impact on encapsulation efficiency.[18,20]

6.5 Morphology

Morphological characterization provides information regarding nanoparticle architecture, internal organization, and structural integrity.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 3, November 2026 Impact Factor: 8.2

Common techniques include:
Transmission Electron Microscopy (TEM)
Cryogenic TEM
Atomic Force Microscopy (AFM)
Small-Angle X-ray Scattering (SAXS)
Cryo-TEM has become the preferred technique because it preserves nanoparticles in their hydrated state without introducing drying artifacts.[22]

6.6 Stability studies

Stability directly influences clinical translation.
Important parameters include:
Particle size changes
PDI variation
Lipid oxidation
RNA degradation
Leakage of encapsulated drug
Freeze–thaw stability
Recent studies have highlighted the importance of optimized cryoprotectants and storage conditions to preserve mRNA-LNP formulations during long-term storage.[23]

Table 5. Physicochemical parameters and their biological significance

Parameter	Analytical method	Biological significance
Particle size	DLS, NTA	Biodistribution, circulation time
PDI	DLS	Batch uniformity
Zeta potential	Electrophoretic light scattering	Colloidal stability
Encapsulation efficiency	Ribogreen assay, HPLC	Therapeutic potency
Morphology	TEM, Cryo-TEM, AFM	Structural integrity
Stability	Accelerated stability studies	Shelf life

VII. MECHANISMS OF CELLULAR UPTAKE AND INTRACELLULAR DELIVERY

The delivery of lipid nanoparticles' therapeutic cargo into the cytoplasm of target cells is just as important to their ultimate success as their ability to reach target tissues. Protein corona formation, cellular recognition, endocytosis, intracellular trafficking, endosomal escape, and cytoplasmic release are all highly synchronized biological processes involved in this process. Every stage is a possible obstacle that affects the effectiveness of treatment..[16]

7.1 Protein corona formation

Immediately after systemic administration, plasma proteins adsorb onto the nanoparticle surface, forming a dynamic protein corona.
Rather than being merely a passive coating, the protein corona influences:
Cellular recognition
Organ distribution
Immune clearance
Therapeutic efficacy
For example, adsorption of apolipoprotein E (ApoE) promotes hepatic uptake by facilitating receptor-mediated internalization. This mechanism partly explains the natural liver tropism of many LNP formulations.[24]

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 3, November 2026 Impact Factor: 8.2

7.2 Cellular uptake mechanisms

LNPs enter cells primarily through endocytosis.

Major pathways include:

Clathrin-mediated endocytosis

Caveolae-mediated endocytosis

Macropinocytosis

Clathrin-independent pathways

The predominant pathway varies according to particle size, lipid composition, cell type, and the surrounding biological environment.[1,5]

7.3 Intracellular trafficking

Following internalization, LNPs are transported sequentially through:

Early endosome → Late endosome → Lysosome

Without successful endosomal escape, therapeutic cargo is ultimately degraded within lysosomes.

Consequently, intracellular trafficking represents one of the major determinants of delivery efficiency.[26]

7.4 Endosomal escape

The greatest biological barrier to the transfer of non-viral nucleic acids is still endosomal escape. Only a small percentage of nanoparticles release their cargo into the cytoplasm prior to lysosomal destruction, despite the fact that most are successfully internalized. According to available data, ionizable lipids interact with anionic phospholipids in acidic endosomes after becoming protonated, which destabilizes the membrane and encourages cargo release.

Therefore, one of the main goals of current LNP research is to improve endosomal escape.[9,16]

7.5 Cytoplasmic release and therapeutic action

Once released into the cytoplasm:

mRNA undergoes translation into therapeutic proteins.

siRNA is incorporated into the RNA-induced silencing complex (RISC), resulting in degradation of complementary mRNA.

CRISPR systems mediate targeted genome editing.

Successful cytoplasmic delivery therefore represents the final objective of LNP-mediated intracellular transport.[4]

Table 6. Biological barriers encountered during intracellular delivery

Biological barrier	Consequence	Current strategies
Protein corona	Altered biodistribution	Surface engineering
Cellular membrane	Limited uptake	Ligand-mediated targeting
Endosomal membrane	Cargo degradation	Ionizable lipids
Lysosomal degradation	Reduced efficacy	Enhanced endosomal escape
Cytoplasmic transport	Reduced bioavailability	Rational lipid design

VIII. APPLICATIONS OF LIPID NANOPARTICLES IN DRUG DELIVERY

Lipid nanoparticles (LNPs) have many uses outside of nucleic acid therapy. They are appealing carriers for many therapeutic treatments due to their biocompatibility, capacity to encapsulate both hydrophilic and lipophilic molecules, controlled drug-release properties, and ability to get past biological barriers. LNPs increase therapeutic efficacy, decrease systemic toxicity, improve tissue-specific drug accumulation, and improve pharmacokinetic behavior as compared to traditional formulations. Applications in oncology, infectious diseases, inflammatory conditions, diseases of the central nervous system (CNS), pulmonary delivery, ophthalmic therapy, and protein therapies have been further increased by recent developments in lipid engineering and surface functionalization.(17)

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, November 2026
Impact Factor: 8.2

8.1 Cancer therapy

One of the most studied uses of LNP-mediated medication delivery is still cancer. Conventional chemotherapy drugs frequently have substantial systemic toxicity, limited therapeutic windows, and poor selectivity. By increasing tumor accumulation through the increased permeability and retention (EPR) effect while concurrently lowering off-target exposure, LNPs get around several of these restrictions.

Doxorubicin, paclitaxel, docetaxel, cisplatin, irinotecan, and other molecularly targeted drugs have all been studied for administration via LNP formulations. Encapsulation increases intratumoral drug concentrations, extends systemic circulation, and shields these medications from premature breakdown. Additionally, ligand-modified LNPs containing transferrin, folate, peptides, or antibodies have shown improved receptor-mediated uptake by cancerous cells, increasing therapeutic selectivity.

LNPs are now essential to cancer immunotherapy, going beyond traditional chemotherapy. They are increasingly used to deliver immune checkpoint modulators, cytokines, immuno-stimulatory mRNA, and tumor-associated antigens. These formulations reduce systemic immune-related side effects while stimulating cytotoxic T lymphocytes, activating antigen-presenting cells, and promoting long-lasting anticancer immune responses. The translational potential of LNP-mediated immunotherapy has been further demonstrated by recent clinical trials of mRNA cancer vaccines.

8.2 Delivery of poorly soluble drugs

About 40% of newly discovered medications have poor water solubility, which results in inadequate dissolution, uneven absorption, and reduced oral bioavailability. LNPs provide a useful way to circumvent these limitations by dissolving hydrophobic drugs within their lipid matrix.

Improved dissolving enhances gastrointestinal absorption and reduces systemic exposure variability. LNPs have therefore been successfully investigated for Biopharmaceutics Classification System (BCS) Class II and Class IV drugs, including several antifungal, anticancer, anti-inflammatory, and cardiovascular treatments. When compared to conventional formulations, lipid nanoparticles frequently exhibit higher oral absorption and improved therapeutic efficacy.[27]

8.3 Central nervous system (CNS) drug delivery

One of the biggest barriers to the successful treatment of neurological disorders is still the blood-brain barrier (BBB). Tight endothelial junctions, active efflux transporters, and enzymatic degradation prevent the majority of therapeutic compounds from passing through the blood-brain barrier.

Better brain delivery has been shown by surface-modified LNPs that can engage with endogenous transport systems. Receptor-mediated transcytosis across the blood-brain barrier is facilitated by ligands such transferrin, lactoferrin, apolipoprotein E mimetics, and cell-penetrating peptides. Alzheimer's disease, Parkinson's disease, glioblastoma, epilepsy, and Huntington's disease are among the conditions for which these systems are presently being studied. Despite positive preclinical outcomes, interpatient heterogeneity and complex BBB physiology make consistent clinical translation difficult.[28]

8.4 Pulmonary drug delivery

For respiratory infections, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and pulmonary fibrosis, pulmonary administration is especially beneficial since it offers direct access to the respiratory epithelium. LNPs enhance drug deposition, increase lung tissue residence duration, and prevent the breakdown of delicate biologics like mRNA. Preclinical research on aerosolized LNP formulations for inhaled RNA therapies has shown promising results. There is a lot of interest in treating both hereditary and acquired respiratory disorders because nucleic acids can be delivered directly to pulmonary tissues.[29]

8.5 Ocular drug delivery

Rapid tear turnover, corneal barriers, and nasolacrimal drainage restrict drug delivery to ocular tissues. The bioavailability of conventional eye drops is often less than 5%.

LNPs allow prolonged drug release, increase corneal penetration, and extend precorneal residence time. Their application in glaucoma, age-related macular degeneration, diabetic retinopathy, corneal inflammation, and ocular

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 3, November 2026 Impact Factor: 8.2

infections has been investigated recently. Mucoadhesive polymer surface modification improves treatment efficacy and ocular retention even more.[30]

8.6 Protein and peptide delivery

Despite their remarkable therapeutic specificity, proteins and peptides have low membrane permeability and are quickly broken down by enzymes.

LNPs enhance intracellular delivery while shielding these delicate biomolecules from proteolysis. Insulin, monoclonal antibodies, growth hormones, cytokines, and enzyme replacement treatments are among the current research topics (18). By increasing stability and lowering the frequency of administration, these methods may greatly increase the clinical value of biologics.[31]

Table 7. Therapeutic applications of lipid nanoparticles in drug delivery

Therapeutic area	Representative drugs	Major advantages
Cancer	Doxorubicin, Paclitaxel	Targeted delivery, reduced toxicity
CNS disorders	Dopamine agonists, Neuroprotective agents	BBB penetration
Pulmonary diseases	mRNA, Antibiotics	Localized delivery
Ocular diseases	Anti-VEGF agents	Sustained ocular residence
Protein therapeutics	Insulin, Growth factors	Improved stability

IX. APPLICATIONS OF LIPID NANOPARTICLES IN GENE DELIVERY

Although gene therapy is one of the most revolutionary fields of contemporary medicine, its therapeutic success has historically been constrained by the safe and effective intracellular delivery of nucleic acids. Although viral vectors have a high transfection efficiency, they have drawbacks such as immunogenicity, a small cargo capacity, insertional mutagenesis, and manufacturing complexity. Because they combine high encapsulation efficiency, excellent safety profiles, scalable manufacturing, and transitory gene expression without genomic integration, LNPs have become the most popular non-viral option.[1,2,4]

9.1 Messenger RNA (mRNA) delivery

LNPs are now the gold standard for mRNA delivery thanks to the widespread use of mRNA vaccines against COVID-19. Encapsulation enhances cellular absorption, shields mRNA from nuclease destruction, and encourages effective cytoplasmic translation. Research on mRNA treatments for infectious illnesses, cancer vaccines, protein replacement therapy, and regenerative medicine has surged as a result of this clinical success.

Enhancing tissue-specific targeting, lowering innate immune activation, and increasing protein expression while preserving good safety profiles are the key goals of recent studies.[4]

9.2 Small interfering RNA (siRNA)

siRNA therapies use RNA interference (RNAi) to silence genes that cause disease. Patisiran's clinical approval proved that non-viral lipid systems may accomplish therapeutically significant gene silencing and validated LNP-mediated siRNA delivery.

Treatments for genetic diseases, hypercholesterolemia, liver abnormalities, fibrosis, viral infections, and metabolic diseases are now undergoing clinical development. The goal of ongoing lipid chemistry optimization is to extend siRNA delivery outside of hepatic regions.[3,8]

9.3 MicroRNA (miRNA)

Numerous cellular processes linked to proliferation, apoptosis, inflammation, and tumor growth are regulated by microRNAs.

In order to reestablish normal gene regulation in cancer, cardiovascular disease, neurological illnesses, and chronic inflammatory conditions, LNPs have been studied for the transport of miRNA mimics and anti-miRNA

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 3, November 2026 Impact Factor: 8.2

oligonucleotides. Despite its potential, tissue selectivity and intracellular delivery issues continue to restrict practical translation.[32]

9.4 DNA delivery

Compared to mRNA delivery, plasmid DNA delivery is significantly more difficult since it necessitates transit across both cellular and nuclear membranes.

LNPs improve cellular absorption while shielding plasmid DNA from deterioration. Applications include experimental gene therapy, protein replacement, and DNA vaccinations. However, compared to mRNA therapies, nuclear transport continues to be a significant obstacle that restricts transfection efficiency.[33]

9.5 CRISPR-Cas gene editing

CRISPR-Cas technologies provide previously unheard-of accuracy in fixing mutations that cause disease. However, one of the biggest obstacles to clinical gene editing is still effective in vivo delivery.

Because LNPs circumvent many of the drawbacks of viral vectors, they are being used more and more to carry Cas9 mRNA, guide RNA, and related editing components. Recent research has shown that genes linked to inherited liver diseases, hypercholesterolemia, and transthyretin amyloidosis can be successfully edited in vivo. To expand gene editing beyond the liver, techniques including tailored ionizable lipids and selective organ targeting (SORT) nanoparticles are being developed.[34]

9.6 Future directions in gene delivery

Future LNP-based gene delivery will likely focus on:

Organ-selective nanoparticles

Programmable ionizable lipids

AI-assisted lipid discovery

Combination RNA therapeutics

Personalized gene therapy

Repeat-dose formulations with reduced immunogenicity

These advances are expected to broaden the therapeutic landscape of precision medicine.[35]

Table 8. Gene therapy applications of lipid nanoparticles

Therapeutic cargo	Major application	Clinical status
mRNA	Vaccines, protein replacement	Approved and clinical use
siRNA	Gene silencing	Approved and expanding
miRNA	Gene regulation	Preclinical/early clinical
DNA	DNA vaccines	Experimental
CRISPR-Cas	Genome editing	Early clinical development

X. CLINICAL TRANSLATION AND APPROVED LIPID NANOPARTICLE-BASED THERAPEUTICS

One of the most important developments in pharmaceutical nanotechnology is the effective clinical translation of lipid nanoparticles (LNPs). Due to difficulties with formulation stability, toxicity, large-scale production, and intracellular administration, LNPs were mainly limited to preclinical research for many years. The production of clinically authorized LNP-based medications has now been made possible by developments in ionizable lipid chemistry, microfluidic manufacturing, and quality control, confirming LNPs as a secure and efficient non-viral delivery system.

The U.S. Food and Drug Administration (FDA) approved patisiran (Onpattro®) in 2018, marking a significant milestone in the clinical development of LNPs. The first siRNA treatment authorized for clinical use was patisiran, which showed that lipid nanoparticles could effectively transport RNA molecules to hepatocytes, leading to clinically significant gene silencing for inherited transthyretin-mediated amyloidosis. Investment in RNA-based treatments was greatly boosted by this approval, which proved proof-of-concept for RNA interference therapy.[3]

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, November 2026
Impact Factor: 8.2

The greatest demonstration of LNP technology came during the COVID-19 pandemic. The rapid development and global deployment of **BNT162b2 (Comirnaty®)** and **mRNA-1273 (Spikevax®)** illustrated that LNPs could protect unstable mRNA molecules, facilitate intracellular delivery, and support large-scale commercial manufacturing. These vaccines not only demonstrated remarkable efficacy against SARS-CoV-2 but also established a regulatory pathway for future mRNA therapeutics. The widespread clinical success of these vaccines transformed LNPs from an emerging delivery system into an established pharmaceutical platform.[4]

Many LNP-based treatments have reached clinical development as a result of these achievements. Therapeutic cancer vaccines, protein replacement therapies, gene-editing systems, vaccines against infectious diseases, treatments for autoimmune diseases, and unusual genetic illnesses are all under investigation. Additionally, LNPs are being investigated for personalized cancer immunotherapy, which uses lipid nanoparticles to deliver patient-specific tumor neoantigens that are encoded within mRNA molecules to elicit unique immune responses.[36]

Beyond vaccines, CRISPR-Cas gene-editing treatments have advanced significantly. Cas9 mRNA and guide RNA are delivered directly to target tissues using LNPs in a number of experimental products. In contrast to viral vectors, LNP-mediated delivery minimizes the possibility of off-target genome editing and lowers the risk of extended nuclease activity by producing transitory expression of gene-editing components. For therapeutic genome editing, this transitory delivery profile is thought to provide a significant safety benefit.[34] Significant translational obstacles still exist despite impressive clinical advancements. Because adsorption of apolipoprotein E (ApoE) promotes receptor-mediated uptake by hepatocytes, the majority of therapeutically authorized LNPs preferentially accumulate in the liver.

As a result, significant research efforts are focused on biodegradable ionizable lipids that can increase tissue selectivity, ligand-functionalized LNPs, and selective organ-targeting (SORT) nanoparticles. Successful clinical translation now depends heavily on large-scale manufacturing. Nanoparticles with a limited size distribution, excellent encapsulation effectiveness, and regulated particle size can be produced consistently using microfluidic mixing technology. These manufacturing innovations promote quick commercial-scale production and make it easier to comply with current Good Manufacturing Practice (cGMP) regulations. Additionally, as the number of clinical candidates for LNP-based medications keeps growing, regulatory bodies are continually upgrading quality standards and guidance papers.[40]

Table 9. Selected clinically approved and advanced lipid nanoparticle therapeutics

Product	Therapeutic cargo	Clinical indication	Regulatory status
Onpattro® (Patisiran)	siRNA	Hereditary transthyretin amyloidosis	FDA approved (2018)
Comirnaty®	mRNA	COVID-19	FDA approved
Spikevax®	mRNA	COVID-19	FDA approved
mRESVIA®	mRNA	Respiratory syncytial virus (RSV)	FDA approved (2024)
Multiple investigational products	mRNA / CRISPR	Cancer, rare diseases, gene editing	Clinical trials

XI. SAFETY, TOXICITY, AND REGULATORY CONSIDERATIONS

Lipid nanoparticles have a far better safety profile than many viral vectors and persistently cationic delivery methods, but their clinical use necessitates a thorough assessment of long-term safety, toxicity, immunogenicity, biodistribution, and biodegradation. Understanding the biological interactions that affect both therapeutic efficacy and potential side effects has become more important as a result of the quick development of LNP-based treatments. The chemical makeup of ionizable lipids is one of the main factors that determines LNP safety. Permanently cationic lipids frequently cause dose-dependent cytotoxicity, inflammatory reactions, complement activation, and membrane rupture. Ionizable lipids, on the other hand, only become protonated in acidic intracellular compartments and remain electrically neutral at physiological pH, which minimizes nonspecific interactions with healthy tissues and plasma

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 3, November 2026 Impact Factor: 8.2

proteins.Nevertheless, lipid metabolism, degradation products, and repeated administration continue to require careful evaluation during preclinical and clinical development.[37]

Another crucial aspect of safety is immunogenicity. By decreasing opsonization and phagocytic clearance, polyethylene glycol (PEG)-lipids extend systemic circulation; nonetheless, some people may develop anti-PEG antibodies after repeated treatment. Rapid blood clearance and, in rare cases, hypersensitivity reactions have been linked to the existence of these antibodies. As a result, a lot of work is being done to create cleavable PEG-lipids and alternative stealth coatings that minimize immune responses while maintaining prolonged circulation.[38]

The clinical safety profile of LNPs is further influenced by biodistribution and organ-specific toxicity. Many formulations concentrate primarily in the liver after systemic delivery due to interactions with circulating apolipoproteins. Excessive hepatic accumulation may raise the risk of temporary liver enzyme rise and other hepatic consequences during repeated administration, despite the fact that this trait helps treatments for hepatic illnesses.Therefore, comprehensive pharmacokinetic and toxicological studies remain essential during product development.[24,37]

Reactogenicity is very important when it comes to vaccination formulations. Among the most often reported side effects after administering LNP-based mRNA vaccines include local injection site pain, temporary fever, exhaustion, headache, and myalgia. These responses are usually self-limiting and indicate the activation of innate immune pathways. In order to maintain immunogenic efficacy while lowering reactogenicity, ongoing research aims to optimize lipid composition and RNA design.[39]

From a regulatory standpoint, LNP-based treatments are assessed using accepted pharmaceutical quality standards in addition to extra factors unique to nanomedicine. Particle size distribution, encapsulation effectiveness, lipid composition, residual solvents, sterility, endotoxin concentration, and long-term stability are among the crucial quality criteria that regulatory bodies demand thorough analysis of. To guarantee uniformity and repeatability from batch to batch, manufacturing procedures must adhere to cGMP regulations. The FDA and the European Medicines Agency (EMA) are improving guidelines for nanomedicines, RNA therapies, and innovative delivery systems as the number of approved LNP products keeps rising.

Standardized analytical techniques, harmonized quality standards, post-marketing surveillance, and long-term safety monitoring are anticipated to receive more attention in the regulatory environment of the future. Supporting the ongoing clinical development of LNP technology into gene editing, personalized medicine, and next-generation RNA therapies will need these actions.[(21)]

Table 10. Major safety concerns associated with lipid nanoparticles and current mitigation strategies

Safety concern	Underlying cause	Current mitigation strategy
Immunogenicity	Innate immune activation, anti-PEG antibodies	Optimized lipid chemistry, cleavable PEG-lipids
Hepatic accumulation	ApoE-mediated liver uptake	Organ-selective lipid formulations
Complement activation	Surface interactions with plasma proteins	Ionizable lipids, optimized formulation
Reactogenicity	Cytokine release and innate immune stimulation	Modified RNA, optimized lipid composition
Manufacturing variability	Batch-to-batch inconsistency	Microfluidic production, cGMP compliance

XII. CHALLENGES AND FUTURE PERSPECTIVES

Lipid nanoparticles (LNPs) have transformed the delivery of medications and nucleic acids, but their wider clinical use is still constrained by a number of scientific, technological, and legal issues. Expanding LNP technology beyond liver diseases and vaccines to precision medicine, regenerative therapy, and gene editing requires addressing these

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 3, November 2026 Impact Factor: 8.2

constraints. The focus of recent research has changed from proving that LNP-mediated delivery is feasible to improving tissue selectivity, intracellular trafficking, long-term safety, and scalable manufacturing.

12.1 Limited tissue specificity

The overwhelming buildup of existing LNP formulations in the liver after systemic injection is one of their biggest problems. Apolipoprotein E (ApoE) adsorption onto the nanoparticle surface, which enables receptor-mediated absorption by hepatocytes, is the main cause of this liver tropism. This characteristic greatly restricts the therapeutic potential of LNPs for conditions affecting the brain, lungs, skeletal muscle, heart, and other extrahepatic tissues, even though it is beneficial for treating hepatic ailments.

Researchers have created a number of targeting techniques to get around this restriction. In order to promote selective cellular uptake, active targeting uses ligands like antibodies, peptides, aptamers, polysaccharides, or receptor-specific compounds linked to the nanoparticle surface. In order to boost the accumulation of nanoparticles, passive targeting makes use of disease characteristics such increased vascular permeability within tumors. More recently, selective organ targeting (SORT) nanoparticles have demonstrated that relatively small modifications in lipid composition can redirect biodistribution toward organs such as the lungs or spleen without fundamentally altering the nanoparticle architecture. These approaches represent important advances toward tissue-specific drug and gene delivery[13,24].

12.2 Inefficient endosomal escape

Before lysosomal breakdown takes place, therapeutic cargo must leave endosomal compartments after successful cellular uptake. Endosomal escape is still one of the least effective processes in intracellular delivery, despite significant advancements in nanoparticle engineering. Only a tiny percentage of internalized nucleic acids successfully enter the cytoplasm, according to experimental research, significantly lowering therapeutic efficacy.

In order to enhance cytoplasmic release, current research focuses on creating ionizable lipids with optimal pKa values, branching hydrophobic tails, biodegradable linkers, and membrane-disruptive characteristics. Other strategies include fusogenic phospholipids, pH-responsive lipids, and stimuli-responsive nanoparticles that can release cargo in reaction to changes in the intracellular environment. One of the top goals in the development of next-generation LNPs is still to improve endosomal escape.[41]

12.3 Long-term safety and immunogenicity

Concerns about long-term toxicity, immunological activation, complement activation, and the development of anti-PEG antibodies are raised by repeated administration, despite the fact that clinically authorized LNP formulations have shown acceptable safety profiles. By decreasing protein adsorption, polyethylene glycol (PEG)-lipids increase systemic circulation. However, frequent exposure might cause anti-PEG antibodies, which speed up blood clearance and cause hypersensitivity reactions in certain people.

Researchers are creating cleavable PEG-lipids, zwitterionic surface coatings, biodegradable ionizable lipids, and other stealth polymers that reduce immunogenicity while maintaining extended circulation in order to solve these problems. As LNP-based treatments spread to chronic conditions requiring regular administration, ongoing long-term clinical observation will be crucial.[17,37,38].

12.4 Manufacturing and scale-up

Commercial production of LNPs requires highly reproducible manufacturing processes capable of consistently producing nanoparticles with uniform size, encapsulation efficiency, and physicochemical properties. Although microfluidic mixing has substantially improved manufacturing reproducibility, challenges remain regarding large-scale continuous production, process optimization, quality assurance, and cost reduction.

Emerging technologies such as continuous-flow microfluidics, automated process analytical technology (PAT), Quality by Design (QbD), and machine learning-assisted process optimization are expected to improve production efficiency while ensuring compliance with Good Manufacturing Practice (GMP) standards[18,20,40].

12.5 Artificial intelligence in LNP development

Recently, machine learning and artificial intelligence (AI) have become effective techniques for speeding up the production of nanoparticles. Formulation optimization has historically involved a great deal of trial-and-error

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, November 2026
Impact Factor: 8.2

experimentation with a variety of lipid combinations and process factors. Large experimental datasets can be analyzed, physicochemical behavior can be predicted, ionizable lipid pKa values can be estimated, formulation composition may be optimized, and attractive lipid candidates can be found prior to laboratory synthesis using AI-driven computational models.

It is anticipated that integrating AI with computational chemistry, molecular dynamics simulations, and high-throughput screening can greatly shorten development times and increase formulation efficiency. AI-assisted formulation design may become a common practice in the creation of medicinal nanoparticles as computer power increases.[14,35]

12.6 Personalized nanomedicine

One of the most promising uses of LNP technology in the future is personalized medicine. Treatments based on a patient's genetic profile are becoming more and more possible thanks to developments in transcriptomics, genomics, and molecular diagnostics. LNPs offer a versatile delivery mechanism that can carry tailored nucleic acids, such as patient-specific RNA therapies, gene-editing systems, and customized cancer vaccinations. The ability to quickly develop patient-specific treatments based on tumor genomic sequencing has been proven by the effectiveness of customized mRNA cancer vaccines. The use of LNPs in precision medicine is anticipated to grow as formulation technology, computational design, and manufacturing flexibility continue to advance.[42]

Table 11. Major challenges and future strategies for lipid nanoparticle development

Current challenge	Impact on therapy	Future strategy
Liver-dominant biodistribution	Limited treatment of extrahepatic diseases	Organ-selective lipid nanoparticles (SORT), ligand-mediated targeting
Inefficient endosomal escape	Reduced intracellular delivery	Novel ionizable lipids, fusogenic lipids, pH-responsive systems
PEG-related immunogenicity	Accelerated blood clearance, hypersensitivity	Cleavable PEG-lipids, alternative stealth polymers
Manufacturing complexity	Batch variability and production cost	Continuous microfluidics, PAT, QbD, AI-assisted optimization
Limited predictive formulation design	Time-consuming development	Artificial intelligence, molecular simulations, high-throughput screening

XIII. CONCLUSION

Lipid nanoparticles have transformed the field of pharmaceutical drug delivery by providing a safe, efficient, and clinically validated way to administer both conventional pharmaceuticals and nucleic acid therapies. Their remarkable successes in messenger RNA vaccines and RNA interference therapies have demonstrated the tremendous potential of non-viral delivery systems, making LNPs one of the most important developments in contemporary nanomedicine. In conclusion, lipid nanoparticles have evolved from experimental delivery techniques into a pharmaceutical platform with a variety of therapeutic uses. Pharmaceutical scientists, chemists, molecular biologists, engineers, computational researchers, clinicians, and regulatory agencies will need to continue working together in order to develop the next generation of intelligent lipid nanocarriers that can deliver safer, more effective, and highly targeted therapies for a variety of diseases.

REFERENCES

1. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nature Reviews Materials. 2021;6(12):1078-1094.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, November 2026
Impact Factor: 8.2

2. Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid nanoparticles—From liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 2021;15(11):16982-17015.
3. Akinc A, Maier M, Manoharan M, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nature Nanotechnology. 2019;14(12):1084-1087.
4. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nature Reviews Drug Discovery. 2018;17(4):261-279.
5. Eygeris Y, Gupta M, Kim J, Sahay G. Chemistry of lipid nanoparticles for RNA delivery. Accounts of Chemical Research. 2022;55(1):2-12.
6. Mitchell MJ, Padilla MS, et al. Breaking the final barrier: Evolution of cationic and ionizable lipid structure in lipid nanoparticles to escape the endosome. Advanced Drug Delivery Reviews. 2024.
7. Thi TTH, Suys EJA, Lee JS, Nguyen DH, Park KD, Truong NP. Lipid-based nanoparticles in the clinic and clinical trials: From cancer nanomedicine to COVID-19 vaccines. Vaccines. 2021;9(4):359.
8. Cullis PR, Felgner PL. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nature Reviews Drug Discovery. 2024;23(9):709-722.
9. Sabnis S, Kumarasinghe ES, Salerno T, et al. A novel amino lipid series for mRNA delivery: Improved endosomal escape and sustained pharmacology. Molecular Therapy. 2018;26(6):1509-1519.
10. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nature Reviews Materials. 2021;6(12):1078-1094
11. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – A review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics. 2000;50(1):161-177.
12. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. *Advanced Drug Delivery Reviews*. 2002;54(Suppl 1):S131–S155.
13. Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. *Nature Nanotechnology*. 2020;15(4):313–320.
14. Dorsey PJ, Lau CL, Chang TC, Doerschuk PC, D'Addio SM. Review of machine learning for lipid nanoparticle formulation and process development. *Journal of Pharmaceutical Sciences*. 2024;113(12):3413–3433.
15. Kulkarni JA, Witzigmann D, Leung J, et al. On the role of helper lipids in lipid nanoparticle formulations of siRNA. *Nanoscale*. 2019;11(45):21733–21739.
16. Patel S, Ashwanikumar N, Robinson E, et al. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. *Advanced Drug Delivery Reviews*. 2022;188:114416.
17. Kozma GT, Shimizu T, Ishida T, Szebeni J. Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. *Advanced Drug Delivery Reviews*. 2020;154–155:163–175.
18. Mehraji S, DeVoe DL. Microfluidic synthesis of lipid-based nanoparticles for drug delivery: recent advances and opportunities. *Lab on a Chip*. 2024;24(5):1154–1174.
19. . Evers MJW, Kulkarni JA, van der Meel R, et al. State-of-the-art design and rapid-mixing production techniques of lipid nanoparticles for nucleic acid delivery. *Small Methods*. 2018;2(9):1700375.
20. Mehraji S, DeVoe DL. Microfluidic synthesis of lipid-based nanoparticles for drug delivery: recent advances and opportunities. *Lab on a Chip*. 2024;24(5):1154–1174.
21. Maeki M, Kimura N, Sato Y, Harashima H, Tokeshi M. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery. *Journal of Controlled Release*. 2022;344:80–92.
22. Schober GB, Story S, Arya DP. *A careful look at lipid nanoparticle characterization: analysis of benchmark formulations for encapsulation of RNA cargo size gradient.* Scientific Reports. 2024;14:2403.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, November 2026
Impact Factor: 8.2

23. Hallan SS, Sguizzato M, Esposito E, Cortesi R. *Challenges in the Physical Characterization of Lipid Nanoparticles.* Pharmaceutics. 2021;13(4):549.
24. Clogston JD. *Parameters, Methods and Considerations for the Physicochemical Characterization of Liposomal Products.* National Cancer Institute's Nanotechnology Characterization Laboratory Assay Protocols. 2024.
25. Hadjidemetriou M, Kostarelos K. Nanomedicine: Evolution of the nanoparticle corona. *Nature Nanotechnology*. 2017;12(4):288–290.
26. Stewart MP, Lorenz A, Dahlman J, Sahay G. Challenges in carrier-mediated intracellular delivery: moving beyond endosomal barriers. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*. 2016;8(3):465–478.
27. Porter CJH, Trevaskis NL, Charman WN. *Lipid-based formulations as enabling technology for oral delivery of poorly water-soluble drugs.* Nature Reviews Drug Discovery. 2007;6(3):231–248.
28. Mendes M, Sousa JJ, Pais A, Vitorino C. *Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood–brain barrier (BBB) to manage neurological disorders.* Advanced Drug Delivery Reviews. 2022;189:114485.
29. Alwani S, Wasan EK, Badea I. *Solid Lipid Nanoparticles for Pulmonary Delivery of Biopharmaceuticals: A Review of Opportunities, Challenges, and Delivery Applications.* Molecular Pharmaceutics. 2024;21(7):3084–3102.
30. Baig MS, Karade SK, Ahmad A, et al. *Lipid-based nanoparticles: innovations in ocular drug delivery.* Frontiers in Molecular Biosciences. 2024;11:1421959.
31. He Y, Han Y, Shen J. *Local Delivery Strategies for Peptides and Proteins into the CNS: Status Quo, Challenges, and Future Perspectives.* Pharmaceutics. 2023;15(6):1670.
32. Rupaimoole R, Slack FJ. *MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.* Nature Reviews Drug Discovery. 2017;16(3):203–222.
33. Ni R, et al. *Advances in lipids design for LNP-mediated DNA and RNA delivery.* Acta Pharmaceutica Sinica B. 2025.
34. Gillmore JD, Gane E, Taubel J, et al. *CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.* New England Journal of Medicine. 2021;385(6):493–502.
35. Liu Z, Chen J, Xu M, et al. *Programmable lipid nanoparticles for RNA therapeutics: Design principles and clinical translation.* Molecular Therapy – Bioscience. 2026.
36. Kulkarni JA, Witzigmann D, Thomson SB, et al. *The current landscape of nucleic acid therapeutics.* Nature Nanotechnology. 2021;16:630–643.
37. Kim H, Lee S, Kim M, et al. *Inflammatory and immune-mediated toxicity of lipid nanoparticles.* Biomedicine & Pharmacotherapy. 2026;199:119385.
38. Chen Y, Su YC, Roffler SR. *Polyethylene glycol immunogenicity in nanomedicine.* Nature Reviews Bioengineering. 2025;3:742–760.
39. Verbeke R, Lentacker I, De Smedt SC, Dewitte H. *The dawn of mRNA vaccines: The COVID-19 case.* Journal of Controlled Release. 2021;333:511–520.
40. Mehn D, Caputo F, Rösslein M, et al. *Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development.* ACS Materials Au. 2023;3(4):365–402.
41. Chatterjee S, Kon E, Sharma P, Peer D. *Endosomal escape: A bottleneck for LNP-mediated therapeutics.* Proceedings of the National Academy of Sciences of the United States of America. 2024;121(11):e2307800120.
42. Sahin U, Oehm P, Derhovanessian E, et al. *An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.* Nature. 2020;585:107–112.